Navigation Links
MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
Date:2/17/2009

Technology enhances biological activity (regenerative potential) of stem cells and accelerates development of proprietary enhanced therapeutics

GAITHERSBURG, Md., Feb. 17 /PRNewswire-USNewswire/ -- MaxCyte announces today the introduction of its GT(TM) Flow Transfection System at the 4th Annual Stem Cell Summit to be held in New York, NY. The MaxCyte GT(TM) Flow Transfection System is a validated, scalable technology for customizing the biological activity of cells for therapeutic use. This system, which is supported by a US FDA Master File, enables rapid and efficient transfection of any primary cell or cell line with >90% cell viability following loading with a broad range of molecules (proteins, drugs, plasmids, mRNA, miRNA, and siRNA) or combinations thereof, at volumes up to tens of billion cells, processed in under 30 minutes. The MaxCyte GT(TM) Flow Transfection System enables consistent cGMP-compliant cell modification in a closed-system for clinical/commercial scale manufacturing. Appropriate for either cGMP facility or point-of-care use, the GT(TM) Flow Transfection System allows cost-effective delivery with both autologous and allogeneic cellular therapies, customized for enhanced efficacy.

"The MaxCyte GT(TM) Flow Transfection System addresses two of the primary challenges hindering acceleration of effective stem cell therapies. It enables design and development of stem cell products modified to allow for improved regenerative responses and permits robust, automated, cost-effective, cGMP and regulatory-compliant product manufacturing," says Dr. Madhusudan Peshwa, Executive Vice President of Cellular Therapies at MaxCyte. "Such reduction in efficacy and delivery risk in the early-stages of product development can significantly reduce cost, accelerate development, and enhance effectiveness, while providing for novel Intellectual Property around such engineered cell therapy and stem cell products."

"The GT(TM) Flow Transfection System has been validated in a marketed oncology therapy and in multiple phase I/II clinical studies in oncology and regenerative medicine applications with demonstrated ability to customize and enhance biological activity of cells and ensure robust product manufacturing," stated Mr. Douglas Doerfler, Founder, CEO and President of MaxCyte. "We are excited to make available the MaxCyte GT(TM) Flow Transfection System for clinical applications at translational medical centers and to stem cell investigators involved in the discovery and development of novel pathways that facilitate development of proprietary enhanced cellular therapies and novel efficacious small molecule drugs."

Dr. Peshwa will be delivering a technical presentation at 10:25 AM at the 4th Annual Stem Cell Summit. His presentation will provide an overview of MaxCyte's GT(TM) Flow Transfection System and will discuss specific examples of the development of engineered stem cell products that exhibit enhanced biological activity in vitro and in vivo, and will also discuss clinical experiences from ongoing human trials.

About MaxCyte

MaxCyte is the leader in providing clinical/commercial cell modification technologies and technical expertise to enable the development of proprietary enhanced cellular therapeutics to global leaders in life sciences. MaxCyte's unique transfection technology platform enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases. MaxCyte's proprietary cell loading technology provides critical enablement for cell therapeutics targeting a broad range of chronic diseases by allowing the controlled modification of cell function. By providing unparalleled consistency, scalability, and loading efficiency while avoiding the inherent drawbacks of alternative methods, the MaxCyte GT(TM) Flow Transfection System enables the development of proprietary enhanced therapies that cannot otherwise be commercialized. MaxCyte's clinical-grade cell loading technology platform is supported by an FDA Master File and well validated, with multiple products enabled by the MaxCyte technology in clinical development and on market. Building on these experiences, MaxCyte also offers the MaxCyte STX(TM) Scalable Transfection System as a product for sale to biopharmaceutical companies involved in the burgeoning area of cell-based drug screening and small molecule drug discovery.

For more information: http://www.maxcyte.com


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The MaxCyte(R) STX(TM) Scalable Transfection System to be Presented at the Rapid Fire Innovation Session at LabAutomation2009
2. MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery
3. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
4. MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
5. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
6. MaxCyte to Present at BIO-Europe Spring 2008 Conference
7. Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
8. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
9. Max Muscle Introduces First-Ever Probiotics Protein Bar
10. bioMerieux Introduces Surveillance Tool to Fight Healthcare-Associated Infections
11. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)... ... 2016 , ... From wearable devices that can improve performance ... Thursday, December 15th a panel of entrepreneurs, innovators and a Philadelphia Eagles front ... Smart Talk session. Smart Talk will run from 8:30 – 10:30 a.m. at ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... — optogenetics — is key to exciting advances in the study and mapping ... light projected via free-space optics stimulates small, transparent organisms and excites neurons within ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc ... to client demand KbioBox developed a sophisticated “3 click” gene dditing off target ... from KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium , ... the appointment of new CEO James Stickland ... with decades of experience, has served in senior ... where he specialized in expanding a pipeline of ... portfolios. He most recently served as managing director ...
(Date:12/5/2016)... , Dec. 5, 2016  The Office of ... published "Can CT Scans Enhance or Replace Medico ... potential of supporting or replacing forensic autopsies with ... scan. In response to recommendations made ... exploring using CT scans as a potential component ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):